Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV. Fernández de Larrea C, et al. Among authors: sonneveld p. Blood Cancer J. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0. Blood Cancer J. 2021. PMID: 34857730 Free PMC article.
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R. Barjesteh van Waalwijk van Doorn-Khosrovani S, et al. Among authors: sonneveld p. Blood. 2003 Feb 1;101(3):837-45. doi: 10.1182/blood-2002-05-1459. Epub 2002 Oct 3. Blood. 2003. PMID: 12393383 Free article.
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Durie BG, et al. Among authors: sonneveld p. Hematol J. 2003;4(6):379-98. Hematol J. 2003. PMID: 14671610 Review.
International staging system for multiple myeloma.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. Greipp PR, et al. Among authors: sonneveld p. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809451
A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. San Miguel J, et al. Among authors: sonneveld p. Oncologist. 2006 Jan;11(1):51-61. doi: 10.1634/theoncologist.11-1-51. Oncologist. 2006. PMID: 16401713 Free article. Review.
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Orlowski RZ, et al. Among authors: sonneveld p. J Clin Oncol. 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679727 Clinical Trial.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Richardson PG, et al. Among authors: sonneveld p. Blood. 2007 Nov 15;110(10):3557-60. doi: 10.1182/blood-2006-08-036947. Epub 2007 Aug 9. Blood. 2007. PMID: 17690257 Free article. Clinical Trial.
Lenalidomide: a new therapy for multiple myeloma.
Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H. Palumbo A, et al. Among authors: sonneveld p. Cancer Treat Rev. 2008 May;34(3):283-91. doi: 10.1016/j.ctrv.2007.12.005. Epub 2008 Jan 29. Cancer Treat Rev. 2008. PMID: 18230411 Review.
Thalidomide for treatment of multiple myeloma: 10 years later.
Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Palumbo A, et al. Among authors: sonneveld p. Blood. 2008 Apr 15;111(8):3968-77. doi: 10.1182/blood-2007-10-117457. Epub 2008 Feb 1. Blood. 2008. PMID: 18245666 Free article. Review.
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Ludwig H, et al. Among authors: sonneveld p. Blood. 2008 Apr 15;111(8):4039-47. doi: 10.1182/blood-2007-03-081018. Epub 2008 Feb 11. Blood. 2008. PMID: 18268097 Free PMC article.
619 results